Scynexis' BARDA alliance; Bristol Myers' early data for dual-targeting CAR-T
Plus, news about MediciNova, Tolerance Bio, Tanabe, Lepu Medical and Synphatec. Scynexis’ $200M+ BARDA contract: The partnership is for SCY-247, an investigational treatment for serious drug-resistant fungal infections. The pact is ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.